Medicinal Products

Abakavir/Lamivudin Mylan Pharma 600 mg/300 mg filmom obložene tablete

Name Abakavir/Lamivudin Mylan Pharma 600 mg/300 mg filmom obložene tablete
Former Name Abakavir/lamivudin Vale 600 mg/300 mg filmom obložene tablete
Marketing Authorisation Number HR-H-622715617
Active Substance abacavirum, lamivudinum
Pharmaceutical Form filmom obložena tableta
Strength 600 mg + 300 mg
Packaging [MA Number for Packaging] 30 tableta u blisteru, u kutiji  [HR-H-622715617-01]
30 tableta u blisteru s jediničnom dozom, u kutiji  [HR-H-622715617-02]
90 tableta u blisteru, u kutiji  [HR-H-622715617-03]
30 tableta u blisteru, u kutiji, 3 pakiranja u kutiji  [HR-H-622715617-04]
30 tableta u bočici, u kutiji  [HR-H-622715617-05]
Manufacturer McDermott Laboratories Limited, t/a Gerard Laboratories, Dublin 13, Irska
Mylan Hungary Kft, Komárom, Mađarska
Mylan Germany GmbH , Bad Homburg, Hesse, Njemačka
Marketing Authorisation Holder Mylan Ireland Limited, Unit 35/36 Grange Parade, Baldoyle Industrial Estate, Dublin 13, Irska
Marketing Authorisation Date 31.05.2019
MA Period of Validity 10.08.2023
Classification Number UP/I-530-09/15-01/321
Registration Number 381-12-01/30-19-23
Composition jedna filmom obložena tableta sadrži 600 mg abakavira (u obliku abakavirsulfata) i 300 mg lamivudina
Prescription na recept
Type of prescription ograničeni recept
Distribution u ljekarni
Advertising to general public zabranjeno
ATC Code J05AR02
Medicinal product marketed in the Croatia Ne
SmPC download
PL download
Public Assessment Report download
Educational materials
for healthcare professionals
Prezentacija za zdravstvene radnike, verzija 3
Back